Cleo Diagnostics Raises AU$5 Million via Placement; Shares Fall 6%

MT Newswires Live

Dec 18, 2025

Cleo Diagnostics (ASX:COV) raised AU$5 million via a placement of 8.3 million shares at AU$0.60 per share, to institutional investors and existing unrelated shareholders, according to a Thursday filing with the Australian bourse.

The offer price is an 8.4% discount to the company's 15-day volume weighted average price, the filing said.

The company will also issue 833,333 new options, at AU$0.90 each, expiring three years from the date of issue, the filing added.

The funds will be used to launch the company's ovarian cancer test in the US, provide working capital, and for general corporate purposes, the company said.

The placement is expected to settle on Dec. 24, the company said.

Shares of the company fell 6% in recent Thursday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2592282769"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2592282769\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2592282769?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 10:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592282769","market":"fut","top_or_hot":-1,"title":"Cleo Diagnostics Raises AU$5 Million via Placement; Shares Fall 6%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/COV.AU\">Cleo Diagnostics</a> (ASX:COV) raised AU$5 million via a placement of 8.3 million shares at AU$0.60 per share, to institutional investors and existing unrelated shareholders, according to a Thursday filing with the Australian bourse.</p><p>The offer price is an 8.4% discount to the company's 15-day volume weighted average price, the filing said.</p><p>The company will also issue 833,333 new options, at AU$0.90 each, expiring three years from the date of issue, the filing added.</p><p>The funds will be used to launch the company's ovarian cancer test in the US, provide working capital, and for general corporate purposes, the company said.</p><p>The placement is expected to settle on Dec. 24, the company said.</p><p>Shares of the company fell 6% in recent Thursday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cleo Diagnostics Raises AU$5 Million via Placement; Shares Fall 6%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCleo Diagnostics Raises AU$5 Million via Placement; Shares Fall 6%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-18 10:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/COV.AU\">Cleo Diagnostics</a> (ASX:COV) raised AU$5 million via a placement of 8.3 million shares at AU$0.60 per share, to institutional investors and existing unrelated shareholders, according to a Thursday filing with the Australian bourse.</p><p>The offer price is an 8.4% discount to the company's 15-day volume weighted average price, the filing said.</p><p>The company will also issue 833,333 new options, at AU$0.90 each, expiring three years from the date of issue, the filing added.</p><p>The funds will be used to launch the company's ovarian cancer test in the US, provide working capital, and for general corporate purposes, the company said.</p><p>The placement is expected to settle on Dec. 24, the company said.</p><p>Shares of the company fell 6% in recent Thursday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"COV.AU","symbol_name":"Cleo Diagnostics Ltd","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2592282769","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592282769","pubTimestamp":1766023946,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cleo Diagnostics  raised AU$5 million via a placement of 8.3 million shares at AU$0.60 per share, to institutional investors and existing unrelated shareholders, according to a Thursday filing with the Australian bourse.The offer price is an 8.4% discount to the company's 15-day volume weighted average price, the filing said.The company will also issue 833,333 new options, at AU$0.90 each, expiring three years from the date of issue, the filing added.The funds will be used to launch the company's ovarian cancer test in the US, provide working capital, and for general corporate purposes, the company said.The placement is expected to settle on Dec. 24, the company said.Shares of the company fell 6% in recent Thursday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"COV.AU":"Cleo Diagnostics Ltd","BK7067":"生物科技"},"translate_title":"Cleo Diagnostics通过配售筹集500万澳元；股价下跌6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COV.AU":1},"content_text":"Cleo Diagnostics (ASX:COV) raised AU$5 million via a placement of 8.3 million shares at AU$0.60 per share, to institutional investors and existing unrelated shareholders, according to a Thursday filing with the Australian bourse.The offer price is an 8.4% discount to the company's 15-day volume weighted average price, the filing said.The company will also issue 833,333 new options, at AU$0.90 each, expiring three years from the date of issue, the filing added.The funds will be used to launch the company's ovarian cancer test in the US, provide working capital, and for general corporate purposes, the company said.The placement is expected to settle on Dec. 24, the company said.Shares of the company fell 6% in recent Thursday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}